

Datasheet: HCA368

**BATCH NUMBER 160410**

<b>Description:</b>	HUMAN ANTI CEMIPILIMAB
<b>Specificity:</b>	CEMIPILIMAB
<b>Other names:</b>	Libtayo
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD41947ia
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

### Preparation

Purified IgG prepared by affinity chromatography on Protein A

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.01% Thiomersal

### Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

### Immunogen

Cemiplimab

### Specificity

**Human Anti-Cemiplimab Antibody, clone AbD41947ia** is a paratope specific, inhibitory

anti-idiotypic antibody that specifically recognizes the fully human monoclonal antibody cemiplimab. It does not recognize free human programmed death receptor-1 (PD-1) nor cemiplimab in complex with PD-1. The antibody can be used to measure free cemiplimab in patient samples.

Clone AbD41947ia is a fully human recombinant monoclonal antibody with IgG1 isotype and can be used as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 2 nM, and is one of three antibodies with different affinities offered for ADA assays.

A pair of anti-cemiplimab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody can be used as a detection reagent, paired with Anti-Cemiplimab Antibody, clone AbD41947ad ([TZA006](#)) in monovalent Fab format as the capture antibody.

Cemiplimab (Libtayo) is a fully human IgG4/kappa antibody. It has been approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) and for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression. Cemiplimab acts as a checkpoint inhibitor by binding to the PD-1 receptor and blocking its interaction with PD-L1 and PD-L2 ligands.

[View a summary of all anti-cemiplimab antibodies](#)

---

<b>Affinity</b>	The monovalent intrinsic affinity of AbD41947ia was measured as $K_D = 2$ nM by real time, label free molecular interaction analysis on immobilized cemiplimab.
-----------------	---

---

<b>ELISA</b>	Clone AbD41947ia can be used as detection antibody for cemiplimab in a bridging ELISA together with TZA006 as the capture reagent. It can also be used as a surrogate positive control or calibrator in an anti-drug antibody assay.
--------------	--

Protocol: [PK bridging ELISA](#)

Protocol: [ADA bridging ELISA](#)

---

<b>Storage</b>	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
----------------	---

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

<b>Guarantee</b>	12 months from date of despatch
------------------	---------------------------------

---

<b>Acknowledgements</b>	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See <a href="http://bio-rad.com/en-us/trademarks">bio-rad.com/en-us/trademarks</a> for details. Libtayo is a trademark of Regeneron Pharmaceuticals, Inc.
-------------------------	---

---

**Health And Safety Information** Material Safety Datasheet documentation #10094 available at:  
<https://www.bio-rad-antibodies.com/SDS/HCA368>  
10094

---

**Licensed Use** For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

---

**Regulatory** For research purposes only

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

---

## Related Products

### Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI CEMIPILIMAB \(HCA367\)](#)

[HUMAN ANTI CEMIPILIMAB \(HCA369\)](#)

[HUMAN ANTI CEMIPILIMAB \(TZA006\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M395112:220315'

**Printed on 03 May 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)